Skip to main content
Journal cover image

International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis.

Publication ,  Journal Article
Bhatt, DL; Steg, PG; Ohman, EM; Hirsch, AT; Ikeda, Y; Mas, J-L; Goto, S; Liau, C-S; Richard, AJ; Röther, J; Wilson, PWF ...
Published in: JAMA
January 11, 2006

CONTEXT: Atherothrombosis is the leading cause of cardiovascular morbidity and mortality around the globe. To date, no single international database has characterized the atherosclerosis risk factor profile or treatment intensity of individuals with atherothrombosis. OBJECTIVE: To determine whether atherosclerosis risk factor prevalence and treatment would demonstrate comparable patterns in many countries around the world. DESIGN, SETTING, AND PARTICIPANTS: The Reduction of Atherothrombosis for Continued Health (REACH) Registry collected data on atherosclerosis risk factors and treatment. A total of 67,888 patients aged 45 years or older from 5473 physician practices in 44 countries had either established arterial disease (coronary artery disease [CAD], n = 40,258; cerebrovascular disease, n = 18,843; peripheral arterial disease, n = 8273) or 3 or more risk factors for atherothrombosis (n = 12,389) between 2003 and 2004. MAIN OUTCOME MEASURES: Baseline prevalence of atherosclerosis risk factors, medication use, and degree of risk factor control. RESULTS: Atherothrombotic patients throughout the world had similar risk factor profiles: a high proportion with hypertension (81.8%), hypercholesterolemia (72.4%), and diabetes (44.3%). The prevalence of overweight (39.8%), obesity (26.6%), and morbid obesity (3.6%) were similar in most geographic locales, but was highest in North America (overweight: 37.1%, obese: 36.5%, and morbidly obese: 5.8%; P<.001 vs other regions). Patients were generally undertreated with statins (69.4% overall; range: 56.4% for cerebrovascular disease to 76.2% for CAD), antiplatelet agents (78.6% overall; range: 53.9% for > or =3 risk factors to 85.6% for CAD), and other evidence-based risk reduction therapies. Current tobacco use in patients with established vascular disease was substantial (14.4%). Undertreated hypertension (50.0% with elevated blood pressure at baseline), undiagnosed hyperglycemia (4.9%), and impaired fasting glucose (36.5% in those not known to be diabetic) were common. Among those with symptomatic atherothrombosis, 15.9% had symptomatic polyvascular disease. CONCLUSION: This large, international, contemporary database shows that classic cardiovascular risk factors are consistent and common but are largely undertreated and undercontrolled in many regions of the world.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JAMA

DOI

EISSN

1538-3598

Publication Date

January 11, 2006

Volume

295

Issue

2

Start / End Page

180 / 189

Location

United States

Related Subject Headings

  • Thrombosis
  • Risk Factors
  • Registries
  • Prevalence
  • Platelet Aggregation Inhibitors
  • Outpatients
  • Middle Aged
  • Male
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bhatt, D. L., Steg, P. G., Ohman, E. M., Hirsch, A. T., Ikeda, Y., Mas, J.-L., … REACH Registry Investigators, . (2006). International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA, 295(2), 180–189. https://doi.org/10.1001/jama.295.2.180
Bhatt, Deepak L., P Gabriel Steg, E Magnus Ohman, Alan T. Hirsch, Yasuo Ikeda, Jean-Louis Mas, Shinya Goto, et al. “International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis.JAMA 295, no. 2 (January 11, 2006): 180–89. https://doi.org/10.1001/jama.295.2.180.
Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas J-L, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006 Jan 11;295(2):180–9.
Bhatt, Deepak L., et al. “International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis.JAMA, vol. 295, no. 2, Jan. 2006, pp. 180–89. Pubmed, doi:10.1001/jama.295.2.180.
Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas J-L, Goto S, Liau C-S, Richard AJ, Röther J, Wilson PWF, REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006 Jan 11;295(2):180–189.
Journal cover image

Published In

JAMA

DOI

EISSN

1538-3598

Publication Date

January 11, 2006

Volume

295

Issue

2

Start / End Page

180 / 189

Location

United States

Related Subject Headings

  • Thrombosis
  • Risk Factors
  • Registries
  • Prevalence
  • Platelet Aggregation Inhibitors
  • Outpatients
  • Middle Aged
  • Male
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans